FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
2.350
+0.110 (4.91%)
Nov 21, 2024, 12:24 PM EST - Market open
FibroBiologics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
81.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFBLG News
- 2 days ago - FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - GlobeNewsWire
- 7 days ago - FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - GlobeNewsWire
- 8 days ago - FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 23 days ago - FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - GlobeNewsWire
- 24 days ago - FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 - GlobeNewsWire
- 4 weeks ago - FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - GlobeNewsWire
- 5 weeks ago - FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office - GlobeNewsWire
- 5 weeks ago - FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire